Clinical trial
Pirfenidone to Treat Hypertrophic Cardiomyopathy
NCT00011076 · National Heart, Lung, and Blood Institute (NHLBI), NIH · Completed
Key facts
| NCT number | NCT00011076 |
|---|---|
| Title | Pirfenidone to Treat Hypertrophic Cardiomyopathy |
| Official title | Double-Blind Placebo-Controlled Study of Pirfenidone, A Novel Anti-Fibrotic Drug in Symptomatic Patients With Hypertrophic Cardiomyopathy (HCM) Associated With Left Ventricular Diastolic Function |
| Lead sponsor | National Heart, Lung, and Blood Institute (NHLBI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Hypertrophic Cardiomyopathy |
| Intervention type | Drug |
| Interventions | Pirfenidone |
| Enrollment | 50 |
| Start date | Feb 1, 2001 |
| Completion | Apr 1, 2003 |
| First posted | Feb 12, 2001 |
| Last update posted | Mar 4, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: